Safety assessments of SPINRAZA® are based on multiple Phase III, Phase II and open-label studies and include 346 patients, aged from newborns to young adults, who received SPINRAZA® for up to 5 years.1
The long-term safety of SPINRAZA® is being evaluated in ongoing open-label studies in patients with infantile-onset (Type I) and later-onset (Type II/III).1
Adverse reactions related to lumbar puncture reported in CHERISH with an incidence ≥5% higher in SPINRAZA®-treated patients than sham-control patients.1
age 48*Later-onset (Type III) SMA
treated with SPINRAZA®
1. SPINRAZA® Summary of Product Characteristics.